189 related articles for article (PubMed ID: 27581475)
1. Adequate intake of potassium does not cause hyperkalemia in hypertensive individuals taking medications that antagonize the renin angiotensin aldosterone system.
Malta D; Arcand J; Ravindran A; Floras V; Allard JP; Newton GE
Am J Clin Nutr; 2016 Oct; 104(4):990-994. PubMed ID: 27581475
[TBL] [Abstract][Full Text] [Related]
2. Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease.
Oktaviono YH; Kusumawardhani N
Acta Med Indones; 2020 Jan; 52(1):74-79. PubMed ID: 32291375
[TBL] [Abstract][Full Text] [Related]
3. Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients.
Movilli E; Camerini C; Gaggia P; Zubani R; Cancarini G
Am J Nephrol; 2018; 48(2):79-86. PubMed ID: 30071530
[TBL] [Abstract][Full Text] [Related]
4. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
[TBL] [Abstract][Full Text] [Related]
5. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
6. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
7. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA
Cardiovasc Ther; 2012 Jun; 30(3):e156-66. PubMed ID: 21883995
[TBL] [Abstract][Full Text] [Related]
8. ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations.
Mitterbauer C; Heinze G; Kainz A; Kramar R; Hörl WH; Oberbauer R
Nephrol Dial Transplant; 2008 May; 23(5):1742-6. PubMed ID: 18234845
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
10. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
Parikh RV; Nash DM; Brimble KS; Markle-Reid M; Tan TC; McArthur E; Khoshniat-Rad F; Sood MM; Zheng S; Pravoverov L; Nesrallah GE; Garg AX; Go AS
Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006415. PubMed ID: 32873054
[TBL] [Abstract][Full Text] [Related]
11. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
[TBL] [Abstract][Full Text] [Related]
12. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
13. Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study.
Schmidt M; Mansfield KE; Bhaskaran K; Nitsch D; Sørensen HT; Smeeth L; Tomlinson LA
BMJ Open; 2017 Jan; 7(1):e012818. PubMed ID: 28069618
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
15. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System.
Chang AR; Sang Y; Leddy J; Yahya T; Kirchner HL; Inker LA; Matsushita K; Ballew SH; Coresh J; Grams ME
Hypertension; 2016 Jun; 67(6):1181-8. PubMed ID: 27067721
[TBL] [Abstract][Full Text] [Related]
17. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
[TBL] [Abstract][Full Text] [Related]
18. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
[TBL] [Abstract][Full Text] [Related]
19. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Hirai T; Yamaga R; Fujita A; Itoh T
J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
[TBL] [Abstract][Full Text] [Related]
20. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
Beusekamp JC; Tromp J; van der Wal HH; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Rossignol P; Zannad F; Voors AA; van der Meer P
Eur J Heart Fail; 2018 May; 20(5):923-930. PubMed ID: 29327797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]